Skip to content
ECPC - European Cancer Patient Coalition
Contact
  • Policy
    • Innovation
      • Access to Medicines
      • Europe of Disparities in Cancer Care
      • Molecular Testing & Personalised Medicine
      • Biosimilars
      • Immuno-Oncology
    • Health Technology Assessment
      • HTA Legislation
    • Public Health Policies
      • European Partnership for Action Against Cancer (EPAAC)
      • Joint Action on Cancer Control (CanCon)
      • iPAAC
      • Vaccines
      • Brexit
    • Societal Issues
      • Cancer Patients’ Rights
      • Employment
      • Survivorship
      • Carers
      • Right to Be Forgotten
    • Quality of Care
      • Cancer Comorbidities
      • All.Can
      • BenchCan
      • Nutrition
      • Specific Cancers
    • Rare Cancers
      • JARC
      • EURACAN
      • RARECARENet
  • Health and Research
    • European Policy Initiatives
      • 4.UNCAN.eu
      • CanSERV
      • CCI4EU
      • EOSC4Cancer
      • Smart Care
    • Big Data and Personalised Medicine
      • BD4BO PIONEER
      • COMFORT
      • LEGACy
      • Instand-NGS4P
      • INTERVENE
      • T2EVOLVE
      • QUALITOP
      • TIGER
      • OPTIMA
      • AIDAVA
      • CGI-Clinics
      • Lifechamps
    • Patients and Caregivers
      • DIAdIC
      • MyPath
      • PREFERABLE-II
      • RELEVIUM
    • Palliative Care
      • Palliative Sedation
      • Painless
      • INSPIRE
      • Pal-Cycles
    • Treatments
      • Immune-Image
      • ImmunoSABR
      • SALVOVAR
    • Digital Health
      • XpandDH
      • Transition
    • Imaging
      • Imagio
      • IDERHA
    • Prevention
      • ONCODIR
    • Past Projects
      • BD4BO DO-IT
      • DENIM
      • eSMART
      • EUCANCan
      • PREDICT
      • PREFER
  • Get Involved
    • Membership
    • Campaigns
      • Bladder Cancer Awareness Month Campaign
      • Head and Neck Cancer Campaigns 2021
      • Nutrition and Physical Activity
      • Pancreatic Cancer ‘World Pancreatic Cancer Day’ Campaign
      • Personalised Medicine Awareness Month
      • Non Melanoma Skin Cancer Campaign
      • Merkel Cell Carcinoma Awareness Campaign
      • Merkel Cell Carcinoma 2020 Awareness Campaign
      • Breast Cancer
    • Working Groups
      • Rare Cancers Working Group
      • Urological Cancer Working Group
      • The Legal Network for Cancer Patients
    • Partnerships
      • Funding Policy and Good Practices
      • European Medicines Agency
      • Collaborations
      • Graphic Design Kit
    • Industry Supporters
  • TOOLBOX
    • Tools
      • Biobanking
      • Bone Health
      • Clinical Trials Database
      • ESMO Cancer Patient Guides
      • Nutrition Booklet
      • The Immuno-oncology Portal (IOP)
      • Personalised Medicine
      • Non-Melanoma Skin Cancer Web Hub
      • Merkel Cell Carcinoma
      • Cancer Associated Thrombosis (CAT)
      • Health Technology Assessment E-Module
      • Social Media Manual, Cancer Advocacy Academy
      • Biosimilars E-module
      • Genetics and Genomics Testing – A guide for patients E-module
    • References
      • White Papers
      • EU Funded Programmes
    • Publications
    • Resources
  • News and Events
    • News
    • Elections
    • Conference and General Meeting
    • Events
  • About us
    • Our Strategy
    • Our Team
    • Members
    • Vacancies
    • Our History
    • Mission and Vision
    • Transparency
  • Intergroup
Contact

EU Joint Action on Rare Cancers (JARC) recommendations towards implementing the Rare Cancer Agenda 2030

Dear Members,

We are happy to invite you to our next public event: “EU Joint Action on Rare Cancers (JARC) recommendations towards implementing the Rare Cancer Agenda 2030” that will take place on Wednesday, 24th of February 2021 from 16:00 to 17:00 CET.

This event, hosted by the Challenge Cancer Intergroup, is an interesting opportunity to discuss about the implementation of the Rare Cancer Agenda 2030 in the EU.

Despite the rarity of each of the 198 identified rare cancers, collectively they represent 24% of all new cancer cases diagnosed in the EU28 each year. Five-year relative survival is worse for rare cancers (47%) than for common cancers (65%), and differences in survival exist across European countries, therefore suggesting the existence of inequalities in healthcare.

The EU created the European Reference Networks (ERNs) in 2017 on several rare diseases, including four related to rare cancers: ERN on rare adult cancers (ERN EURACAN), ERN on haematological diseases (EuroBloodNet), ERN on paediatric cancer (ERN PaedCan), ERN on genetic tumour risk syndromes (ERN GENTURIS). The shortcoming of these ERNs is the lack of awareness among patients and, as a result, the lack of access to the benefits offered by these networks because access is strictly linked to hospitals.

Also following this evolution in the perception of rare cancers as a distinct issue in the world of oncology, the EU prompted JARC (Joint Action on Rare Cancers). JARC gathered around the same table all stakeholders in the field of rare cancers and rare diseases. The goal of JARC was to contribute to improve health outcomes for patients with rare cancers in the EU maximizing chances of ERNs on rare cancers to be successful.

An agenda on rare cancers was perceived as instrumental to prioritise rare cancers in the agenda of the EU and Member States to minimise the risk that rare cancer patients may be discriminated against simply because of the numbers of the disease they suffer from.

Objectives:

  1. Raise awareness about the EU Joint Action on Rare Cancers (JARC) recommendations for the Rare Cancer Agenda 2030.
  2. Open the debate about their implementation at the national level and the need to activate the ERNs network to make it more accessible for patients.

 

Please register here to ensure your participation in the event.

You can find the draft agenda here.

 

< Back to Events

Donate

x

The fight against cancer is not just for patients, it is vital that we work together.

Your support is greatly appreciated!  Donate now

What happens to your donation?

We understand that when you make a donation, you want to know exactly what happens to your money. We aim to be clear and transparent when it comes to using your contributions in our mission to fight cancer. Your donations not only help us to empower the cancer patient community and make a positive difference to healthcare, treatment and accessibility, but also enable us to:
  • ensure our members are engaged and feel part of an active community through information, training, unique resources, tools, opportunities and networking at a national and European level
  • legitimise our position of cancer patient representatives before decision-makers
  • build a reputation as a cancer patient expert within the scientific community
  • find partners sharing the same vision, values and goals to work together on projects
  • get the media’s attention in order to publish and disseminate our messages
  • make the general public aware and supportive

Subscribe to our newsletter

x

Subscribe

* indicates required

By clicking on the button below I expressly confirm that I have read and understood ECPC Privacy Policy http://ow.ly/i94050BPZx0

For more information on ECPC's policies visit our website http://ow.ly/8XCj50BQasP

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Connect with us

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • Youtube

© ECPC 2023. All rights reserved.

  • Privacy Policy
  • Terms & Conditions
  • Cookie Policy of the of ECPC AISBL